Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants
Nicole Leite Galvão‐Coelho, Wolfgang Marx, Maria Gonzalez, et al.
Psychopharmacology (2021) Vol. 238, Iss. 2, pp. 341-354
Open Access | Times Cited: 122

Showing 1-25 of 122 citing articles:

Major depressive disorder
Wolfgang Marx, Brenda W.J.H. Penninx, Marco Solmi, et al.
Nature Reviews Disease Primers (2023) Vol. 9, Iss. 1
Closed Access | Times Cited: 247
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Lily R. Aleksandrova, Anthony G. Phillips
Trends in Pharmacological Sciences (2021) Vol. 42, Iss. 11, pp. 929-942
Closed Access | Times Cited: 171
Psychedelics and Other Psychoplastogens for Treating Mental Illness
Maxemiliano V. Vargas, Retsina Meyer, Arabo A. Avanes, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 116
Psychedelic Drug Legislative Reform and Legalization in the US
Joshua S. Siegel, James E. Daily, Demetrius A. Perry, et al.
JAMA Psychiatry (2022) Vol. 80, Iss. 1, pp. 77-77
Open Access | Times Cited: 95
Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis
Kwonmok Ko, Emma I Kopra, Anthony J. Cleare, et al.
Journal of Affective Disorders (2022) Vol. 322, pp. 194-204
Closed Access | Times Cited: 90
New and emerging approaches to treat psychiatric disorders
Katherine W. Scangos, Matthew W. State, Andrew H. Miller, et al.
Nature Medicine (2023) Vol. 29, Iss. 2, pp. 317-333
Closed Access | Times Cited: 76
Case analysis of long-term negative psychological responses to psychedelics
Rebecka Bremler, Nancy Katati, Parvinder Shergill, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 52
Psilocybin-assisted therapy for depression: A systematic review and meta-analysis
Sipan Haikazian, David Chen‐Li, Danica E. Johnson, et al.
Psychiatry Research (2023) Vol. 329, pp. 115531-115531
Closed Access | Times Cited: 51
Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies
Natacha Perez, Florent Langlest, Luc Mallet, et al.
European Neuropsychopharmacology (2023) Vol. 76, pp. 61-76
Open Access | Times Cited: 44
Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
Athina-Marina Metaxa, Mike Clarke
BMJ (2024), pp. e078084-e078084
Open Access | Times Cited: 27
Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study
Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 20
Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression
Marcelo Falchi, Fernanda Palhano-Fontes, Isabel Wießner, et al.
Neuropsychopharmacology (2025)
Closed Access | Times Cited: 2
The therapeutic potential of psilocybin: a systematic review
Jan van Amsterdam, Wim van den Brink
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 6, pp. 833-840
Closed Access | Times Cited: 58
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder
Joshua D. Rosenblat, M. Ishrat Husain, Yena Lee, et al.
The Canadian Journal of Psychiatry (2022) Vol. 68, Iss. 1, pp. 5-21
Open Access | Times Cited: 43
Understanding the Mechanisms of Action and Effects of Drugs of Abuse
Daniela-Mădălina Ciucă Anghel, Gabriela Viorela Nițescu, Andreea Taisia Tiron, et al.
Molecules (2023) Vol. 28, Iss. 13, pp. 4969-4969
Open Access | Times Cited: 30
Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review
Oliver Rumle Hovmand, Emil Deleuran Poulsen, Sidse Arnfred, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 7, pp. 649-659
Open Access | Times Cited: 25
The need for establishing best practices and gold standards in psychedelic medicine
Allison A. Feduccia, Gabby Agin-Liebes, Collin M. Price, et al.
Journal of Affective Disorders (2023) Vol. 332, pp. 47-54
Closed Access | Times Cited: 24
Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective
John R. Kelly, Claire M. Gillan, Jack Prenderville, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 51
Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 Receptors in the Head Twitch Response Induced by 5-Hydroxytryptophan and Psilocybin: Translational Implications
Orr Shahar, Alexander Botvinnik, Noam Esh-Zuntz, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 14148-14148
Open Access | Times Cited: 33
Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences
Paweł Orlowski, Anastasia Ruban, Jan Szczypiński, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 8, pp. 987-1000
Open Access | Times Cited: 30
Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial
M. Ishrat Husain, Daniel M. Blumberger, David Castle, et al.
BJPsych Open (2023) Vol. 9, Iss. 4
Open Access | Times Cited: 18
Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm
Daniel Perkins, Jerome Sarris, Susan L. Rossell, et al.
Australian & New Zealand Journal of Psychiatry (2021) Vol. 55, Iss. 12, pp. 1127-1133
Closed Access | Times Cited: 38
Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis
Chia‐Ling Yu, Chih‐Sung Liang, Fu‐Chi Yang, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 4, pp. 938-938
Open Access | Times Cited: 26
Review of otential sychedelic reatments for PTSD
Ryan L. Henner, Matcheri S. Keshavan, Kevin P. Hill
Journal of the Neurological Sciences (2022) Vol. 439, pp. 120302-120302
Closed Access | Times Cited: 26
Psilocybin for Trauma-Related Disorders
Amanda Khan, Ellen Bradley, Aoife O’Donovan, et al.
Current topics in behavioral neurosciences (2022), pp. 319-332
Closed Access | Times Cited: 25
Page 1 - Next Page

Scroll to top